Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Essential Healthcare News.
Press releases published on April 30, 2025

Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results
WALTHAM, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its first quarter 2025 financial results on Wednesday, May 7, 2025, at 8:30 …

BioStem Technologies to Host First Quarter 2025 Financial Results Conference Call on May 12, 2025
POMPANO BEACH, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, announces it …

OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain
Urcosimod phase 2 trial treating Neuropathic Corneal Pain (“NCP”) patients was initiated in October 2024 and designed as a double-masked, randomized, 12-week placebo-controlled trial. OKYO Pharma plans to analyze the efficacy data from the 17 patients who …

Teleflex to Present at the BofA Securities 2025 Health Care Conference
WAYNE, Pa., April 30, 2025 (GLOBE NEWSWIRE) -- Management of Teleflex Incorporated (NYSE: TFX), will be presenting at the BofA Securities 2025 Health Care Conference at the Encore Hotel in Las Vegas, Nevada, on Wednesday, May 14, 2025, at 1:40 p.m. (PT). A …

Teleflex receives FDA 510(k) Clearance for Expanded Indications of the QuikClot Control+™ Hemostatic Device
WAYNE, Pa., April 30, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of an expansion to the Indications for Use of the …

Norwegian Cruise Line Holdings Reports First Quarter 2025 Financial Results
Company delivers solid first quarter performance Full year 2025 profitability guidance maintained MIAMI, April 30, 2025 (GLOBE NEWSWIRE) -- Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) (together with NCL Corporation Ltd. (“NCLC”), “Norwegian Cruise …

Best Steroids for Sale 2025 - Buy Steroids Online Legally for Cutting and Bulking Where to Buy Legal Steroids for Sale OTC - CrazyBulk
Albany, New York, April 30, 2025 (GLOBE NEWSWIRE) -- If you are searching for steroids for sale online, CrazyBulk has an extensive range of bodybuilding steroids that are both legal to buy and great value. Steroids are known for their ability to support …

"Prime Biome Reviews (WARNING: I TRIED IT, Experienced It, and Revealed the Positives, Negatives & Unforeseen)
LOS ANGELES, April 30, 2025 (GLOBE NEWSWIRE) -- I'll be straightforward I’ve experimented with a wide array of probiotics. From well-known capsules found in retail chains to upscale gummies delivered from distant locations, none truly lived up to their …

PL BioScience Launches World’s Only Patented Gamma-irradiated Human Platelet Lysate
New high-quality cell growth supplement for cell manufacturing applications including in regenerative medicine and cell therapies Human Platelet Lysate (HPL) offers a safer and sustainable alternative to Fetal Bovine/ Calf Serum (FBS/FCS) Gamma-irradiated …

Er-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX® (neratinib) for Breast Cancer Patients
ATHENS, Greece and LOS ANGELES, April 30, 2025 (GLOBE NEWSWIRE) -- Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies in the EMEA region, today announced that it has signed an agreement with Puma …

Mountainside Joins Northwell Direct Network to Offer Best-in-Class Addiction Treatment
NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- Mountainside Treatment Center is pleased to be named an in-network provider with Northwell Direct, owned by Northwell Health, New York State’s largest healthcare provider and private employer. Northwell Direct …

DEBRICHEM® gewinnt IIWCG Achievement Award 2025 für Innovation in der Wundversorgung
AMSTERDAM, April 30, 2025 (GLOBE NEWSWIRE) -- DEBRICHEM®, das Spitzenprodukt von DEBx Medical, ist auf der 16. Abu Dhabi Wound Care Conference mit dem IIWCG Achievement Award 2025 für Innovation in der Wundversorgung ausgezeichnet worden. Medien-Snippet. …

DEBRICHEM® Wins 2025 IIWCG Achievement Award for Innovation in Wound Care
AMSTERDAM, April 30, 2025 (GLOBE NEWSWIRE) -- DEBRICHEM®, the flagship product of DEBx Medical has been awarded the IIWCG Achievement Award 2025 for Innovation in Wound Care at the 16th Abu Dhabi Wound Care Conference. Media Snippet. Presented during the …

DEBRICHEM® se voit décerner le prix 2025 IIWCG Achievement Award récompensant l’innovation dans le domaine du soin des plaies
AMSTERDAM, 30 avr. 2025 (GLOBE NEWSWIRE) -- DEBRICHEM®, le produit phare de DEBx Medical, a obtenu le prix IIWCG Achievement Award 2025 récompensant l’innovation dans le domaine du soin des plaies lors de la 16e conférence d’Abu Dhabi sur le soin des …

DEBRICHEM® זכה בפרס ההישגיות של IIWCG לשנת 2025 עבור חדשנות בטיפול בפצעים
אמסטרדם, April 30, 2025 (GLOBE NEWSWIRE) -- DEBRICHEM®, מוצר הדגל של DEBx Medical, זכה בפרס ההישגיות של IIWCG לשנת 2025 עבור חדשנות בטיפול בפצעים ב-16th Abu Dhabi Wound Care Conference. קטע מדיה הכרה זו, שהוענקה במהלך טקס הפתיחה של ADNEC, מטעם הקבוצה הבין …

Best Testosterone Booster Supplements For Men: New Report Reveals Which Products Actually Work.
New York, April 30, 2025 (GLOBE NEWSWIRE) -- WhatBest, a trusted resource for product research and rankings, has officially announced its list of the top 5 best testosterone boosters for men, showcasing five high-performing supplements identified through …

RetinAI and FVS Announce CE-MDR Certification for Co-developed AI-based Diabetic Retinopathy Screening Algorithm, LuxIA®
BERN, Switzerland and MADRID, April 30, 2025 (GLOBE NEWSWIRE) -- RetinAI US Inc. (RetinAI) and Fundación Ver Salud (FVS) are pleased to jointly announce that LuxIA®, their co-developed innovative AI algorithm for Diabetic Retinopathy (DR) screening, has …

Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call
Full results from the completed dose escalation part and dose expansion parts of a Phase 1 study evaluating JNJ-1900 (NBTXR3) after induction chemotherapy for patients with locally advanced or borderline resectable pancreatic cancer to be presented by …

Nanobiotix présente les résultats complets de l’étude de Phase 1 évaluant JNJ-1900 (NBTXR3) dans le cancer du pancréas et organise une conférence téléphonique et webcast
L’ensemble des résultats des parties d’escalade et d’expansion de dose de l’étude de Phase 1 évaluant JNJ-1900 (NBTXR3) après chimiothérapie d’induction chez des patients atteints d’un cancer du pancréas localement avancé ou à la limite de la résécabilité …

Immuno-Oncology Results from Research Collaboration with Léon Bérard Cancer Center Presented at AACR Annual Meeting 2025
Immuno-Oncology Results from Research Collaboration with Léon Bérard Cancer Center Presented at AACR Annual Meeting 2025 New gene expression signature for cancer patients to predict clinical response to immune checkpoint. Potential of signature to enhance …